Individualized Ofatumumab versus Fixed Low-Dose Rituximab in MuSK-Antibody-Positive Myasthenia Gravis: A Multicenter Retrospective Cohort Study. (PubMed, Clin Neurol Neurosurg) - Oct 7, 2026 - "These hypothesis-generating observations suggest OFA, administered at this individualized dosing regimen, may be associated with more sustained 6-month responses than low-dose RTX, warranting validation in prospective controlled trials."
Journal • Retrospective data • CNS Disorders • Immunology • Infectious Disease • Myasthenia Gravis
|
|
Fei Jiang; Guanzhong Shi; Haobing Cai; Huan Yang; Kailin Li; Liu Wang; Qian Zhou; Qiuming Zeng; Ting He; Wei Xiang; Weifan Yin; Xiaohua Dong; Yi Zhong; Yuzhen Ouyang; Zeyi Wen
|